<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-124334</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effects of verapamil alone or associated with trandolapril, on blood pressure, albuminuria and metabolic control in diabetes type 2 patients with arterial hypertension and albuminuria</dc:title>
<dc:description xml:lang="en">The aim of this study was to analyse the effect of the ACE-1, Trandolapril, aloneor with Verapamil on blood pressure, albuminuria and metabolic profile in type2 diabetic patients with hypertension and albuminuria. It was an open multicenter, consecutive and prospective study conducted in 281 patients. There was afour-week wash-out period of antihypertensive drugs, after which we carried outa measurement over a 24-h period of the urinary excretion of albumina (UEA).Blood pressure was recorded after at least 5 minutes of rest in the sitting positionat 1 to 3 minute intervals with a mercury sphygmomanometer in good condition. Average BP was obtained from three consecutive readings. Within treatment changes were analysed using descriptive statistics and t-tests on the change from baseline. Analysis of variance, chi-square and Mc Nemar tests were also used. If after 8 weeks of treatment with Trandolapril 2 mg o.q.d. the patients were nonresponders (mean blood pressure reduction of 5 mmHg or less) or their blood pressure remained uncontrolled (blood pressure &amp;#8805; 140/90 mmHg), Verapamil 180mg o.q.d. was added. Two hundred and thirty patients completed the 12 weeks study. Population included 157 (55.9%) males with an average of 61.7 ± 9.2 years. Baseline measurements were systolic 165.4 ± 14.6 and diastolic 94.8 ± 8.5 mmHg blood pressures, fasting glucose 162.7 ± 43.9 mg/dL, glycosylated hemoglobin  (..) (AU)</dc:description>
<dc:creator>En representación del Grupo de estudio MICROTRAN</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La proteinuria es un predictor de morbi-mortalidad en pacientes hipertensos con diabetes tipo 2; los IECAs son fármacos de elección en estos pacientes; si la respuesta no es suficiente, la asociación de un antagonista del calcio no dihidropiridínico podría ser una alternativa eficaz. El propósito del estudio fue evaluar el efecto del tratamiento con el IECA trandolapril, en monoterapia o asociado a verapamil, sobre la excreción urinaria de albúmina, la PA y el control metabólico en pacientes hipertensos con diabetes tipo 2 y proteinuria. Estudio multicéntrico, prospectivo, secuencial, abierto; período de lavado farmacológico antihipertensivo de 4 semanas; cuantificación de la excreción urinaria de albúmina (EUA) de 24 horas. Medida de PA: media de 3 tomas en sedestación tras reposo, con esfigmomanómetro de mercurio calibrado. Tratamiento inicial contrandolapril 2 mg/día; a los pacientes no respondedores (descenso de PA &amp;#8804; 5 mmHg)o no controlados (PA &amp;#8805; 140/90), se añadió verapamil 180 mg a las 8 semanas. Duración del estudio: 12 semanas. 230 pacientes finalizaron el estudio. Las características basales fueron de la población: 157 (55,9%) hombres; edad media: 61,7 ± 9,2 años. PAS/PAD: 165,4 ± 14,6/94,8 ± 8,5 mmHg. Glucemia:162,7 ± 43,9 mg/dl. HbAlc: 6,8 ± 1,2%. Albuminuria (mg/24 h): 520,9 ± 602.Reducción media de la EUA con el tratamiento: 177,9 ± 24,3 mg/día (..) (AU)</dc:description>
<dc:source>Nefrologia;21(5): 456-463, sept.-oct. 2001. ilus, tab</dc:source>
<dc:identifier>ibc-124334</dc:identifier>
<dc:title xml:lang="es">Efecto del trandolapril, en monoterapia y asociado con verapamil, sobre la presión arterial, albuminuria y control metabólico en pacientes hipertensos con diabetes tipo 2 y albuminuria</dc:title>
<dc:subject>^d422^s22027</dc:subject>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d30965</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7152^s22067</dc:subject>
<dc:subject>^d29640</dc:subject>
<dc:subject>^d31868^s22000</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d23506^s22000</dc:subject>
<dc:subject>^d422</dc:subject>
<dc:subject>^d3942^s22067</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d422^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200110</dc:date>
</metadata>
</record>
</ibecs-document>
